Sherene Loi Joint 2016 COSA and ANZBCTG Annual Scientific Meeting

Sherene Loi

Assoc. Prof Sherene Loi is a Medical Oncologist specialized in breast cancer management as well as clinician scientist with expertise in genomics, immunology and drug development. Her work is focused on developing new therapeutic approaches that may improve outcomes of breast cancer patients. She completed her medical degree (MBBS [Hons] Monash University) in 1996, her Medical Oncology training (FRACP) in 2004 and was awarded her PhD (University of Melbourne) in 2008 on breast cancer genomics. The majority of her PhD and all of her Post-Doc were conducted in Brussels, Belgium (2004-2012). In 2013, she returned to head the newly created Translational Breast Cancer Genomics and Therapeutics laboratory at the Peter MacCallum Cancer Centre, Melbourne, as well as Consultant Medical Oncologist in the Breast Service She is the current lead of the Breast Cancer stream in the Parkville Clinical Trials Unit. Assoc. Prof Loi’s work has led to new insights into the immunology field as well as the clinical relevance and biology of PIK3CA mutations in breast cancer. She has also published on important immunological effects of targeted anti-cancer agents in breast cancer as well as the prognostic and predictive associations of somatic mutations in breast cancer. These findings have led to ongoing international clinical trials. She has over 100 peer- reviewed articles in press or published and has over 5000 citations according to the Web of Science. A/Prof Loi is on the Scientific Advisory Committee of the Australia New Zealand Breast Cancer Trials Group (ANZBCTG), which is the largest breast cancer clinical trials cooperative group in Australia. She also co-chairs the Translational Working Group of the International Breast Cancer Study Group (IBCSG) based in Bern, Switzerland which conducts academic global breast cancer clinical trials in over 16 countries world-wide. She is the current holder of the Cancer Council Victoria John Colebatch Clinical Fellowship. She is a fellow of the Breast Cancer Research Foundation (BCRF), New York. She is the current lead for the Breast Cancer track for the American Society of Clinical Oncology (ASCO).

Abstracts this author is presenting: